Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I first-in-human study of GDC-6599 in healthy adults
NL-OMON52277Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nedizantrep in asthma and chronic cough (6 arms), sponsored by Genentech. Primary endpoints: Incidence and severity of adverse events, Change from baseline in targeted vital signs and 2 more. Started Aug 2021; status: completed.
02
Drugs
nedizantrep
03
Conditions
asthmachronic cough
Beyond the preview
Go deeper on NL-OMON52277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52277.